Muscle and Nerve

Impact of the COVID-19 pandemic on patients with myasthenia gravis: A survey of the Myasthenia Gravis Foundation of America MG patient registry.  67:25-32. 2023

The best and worst of times in therapy development for myasthenia gravis.  67:12-16. 2023

One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry.  66:411-420. 2022

Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE).  64:270-276. 2021

Quantitative analysis of myokymic discharges in radiation versus nonradiation cases.  63:861-867. 2021

hnRNP L is essential for myogenic differentiation and modulates myotonic dystrophy pathologies.  63:928-940. 2021

Acute immune sensory polyradiculopathy: a new variant of Guillain-Barré syndrome.  63:E28-E30. 2021

Clinical exome sequencing in the diagnosis of pediatric neuromuscular disease.  63:304-310. 2021

Metabolic syndrome and peripheral neuropathy.  63:285-293. 2021

Nodal conduction block: A unifying concept.  63:178-180. 2021

Single-institutional reference values for concentric needle jitter analysis using the extrapolated reference values procedure: Comparison to published reference values.  63:113-116. 2021

Assessment of the compound muscle action potential amplitude return time between exercises or tests in the repetitive nerve stimulation test for Lambert-Eaton myasthenic syndrome.  62:742-745. 2020

Clinical features of LRP4/agrin-antibody–positive myasthenia gravis: A multicenter study.  62:333-343. 2020

Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.  62:261-266. 2020

Mouse genotyping in an hour.  61:679-680. 2020

Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment.  60:707-715. 2019

Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis.  60:700-706. 2019

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.  60:14-24. 2019

Repetitive nerve stimulation test in myasthenic crisis.  59:544-548. 2019

Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.  59:201-207. 2019

Short segment sensory nerve stimulation in suspected ulnar neuropathy at the elbow: A pilot study.  59:125-129. 2019

Alterations in mitochondrial fission, fusion, and mitophagic protein expression in the gastrocnemius of mice after a sciatic nerve transection.  58:592-599. 2018

Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry.  58:90-98. 2018

3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome: Concerns regarding presentation of previous studies.  57:E130. 2018

Diagnostic value of the near-nerve needle sensory nerve conduction in sensory inflammatory demyelinating polyneuropathy.  57:414-418. 2018

Genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies.  57:6-15. 2018

Quantification and characterization of grouped type I myofibers in human aging.  57:E52-E59. 2018

Subacute demyelinating polyradiculoneuropathy complicating Epstein–Barr virus infection in GATA2 haploinsufficiency.  57:150-156. 2018

Anti–3-hydroxy-3-methylglutaryl-coenzyme a reductase necrotizing myopathy masquerading as a muscular dystrophy in a child.  56:1177-1181. 2017

Multifocal sensory demyelinating neuropathy: Report of a case.  56:825-828. 2017

International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r.  54:1015-1022. 2016

Ocular LEMS or MLOS.  54:981-982. 2016

Comparisons of ultrasound-estimated intramuscular fat with fitness and health indicators.  54:743-749. 2016

Myotonic dystrophy type 1 presenting with asymmetric winged scapulae.  54:339-340. 2016

Clinical spectrum of valosin containing protein (VCP)-opathy.  54:94-99. 2016

Diagnostic markers of axonal degeneration and demyelination in sensory nerve conduction.  53:866-871. 2016

Amifampridine phosphate (Firdapse^®) is effective and safe in a phase 3 clinical trial in LEMS.  53:717-725. 2016

Acute myofascitis as a manifestation of chronic graft-versus-host disease.  53:327-329. 2016

Myasthenia gravis Lambert-Eaton overlap syndrome.  53:20-26. 2016

Measurement of intramuscular fat by muscle echo intensity.  52:963-971. 2015

Paraneoplastic myeloneuropathy in a man with breast cancer.  52:685-686. 2015

Asymptomatic vasculitic neuropathy.  52:34-38. 2015

Changes in α7β1 integrin signaling after eccentric exercise in heat-shocked rat soleus.  51:562-568. 2015

Mechanosensitivity may be enhanced in skeletal muscles of spinal cord-injured versus able-bodied men.  50:599-601. 2014

Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?.  49:483-486. 2014

One-minute exercise is best for evaluation of postexercise exhaustion in myasthenia gravis.  50:413-416. 2014

A patient diagnosed with Mg at onset and Lems 20 years later.  48:841-842. 2013

The role of chemokines in guillain-barré syndrome.  48:320-330. 2013

A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.  48:76-84. 2013

Single-fiber EMG and clinical correlation in Lambert-Eaton myasthenic syndrome.  47:664-667. 2013

Quantitative neuromuscular ultrasound in the intensive care unit.  47:255-259. 2013

Electromyography tests in patients with implanted cardiac devices are safe regardless of magnet placement.  47:17-22. 2013

Reply.  47:145-146. 2013

Psychometric evaluation of the myasthenia gravis composite using rasch analysis.  45:820-825. 2012

Recommendations for myasthenia gravis clinical trials.  45:909-917. 2012

Subacute brachial diplegia associated with west nile virus myelitis.  45:900-904. 2012

Clinical utility of sensory nerve conduction of medial femoral cutaneous nerve.  45:195-199. 2012

Re: Practice parameters in myasthenia gravis.  44:1001. 2011

Isolation and transcriptome analysis of adult zebrafish cells enriched for skeletal muscle progenitors.  43:741-750. 2011

Practice parameters and focusing research: Plasma exchange for myasthenia gravis.  43:625-626. 2011

Focal conduction block in a case of tarsal tunnel syndrome.  42:452-455. 2010

Intraoperative on-nerve nerve conduction study and conversion factor in the sural nerve.  42:373-378. 2010

Dorsal caudal tail and sciatic motor nerve conduction studies in adult mice: Technical aspects and normative data.  41:850-856. 2010

3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.  40:795-800. 2009

Racial differences in myasthenia gravis in Alabama.  39:328-332. 2009

Construction of an efficient evaluative instrument for myasthenia gravis: The MG composite.  38:1553-1562. 2008

Statins may aggravate myasthenia gravis.  38:1101-1107. 2008

Less is more, or almost as much: A 15-item quality-of-life instrument for myasthenia gravis.  38:957-963. 2008

Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome.  37:572-575. 2008

Myasthenia Gravis and Guillain-Barré syndrome occurring simultaneously in the same patient.  37:544-546. 2008

Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome.  35:178-183. 2007

Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiency.  34:572-576. 2006

Electrodiagnostic criteria for carpal tunnel syndrome in axonal polyneuropathy.  33:747-752. 2006

Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis.  33:500-504. 2006

Adult polyglucosan body disease: A case report of a manifesting heterozygote.  32:675-681. 2005

Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome.  32:515-520. 2005

Myokymia, neuromyotonia, dermatomyositis, and voltage-gated K⁺ channel antibodies.  27:757-760. 2003

Near-nerve needle sensory conduction study of the medial calcaneal nerve: New method and report of four cases of medial calcaneal neuropathy.  26:654-658. 2002

Primary axonal degeneration in tarsal tunnel syndrome: Fact or fiction? [2].  25:301-302. 2002

Relation between in vivo and in vitro measurements of skeletal muscle oxidative metabolism.  24:1665-1676. 2001

Muscle metabolic economy is inversely related to exercise intensity and type II myofiber distribution.  24:654-661. 2001

Distal sensory nerve conduction of the superficial peroneal nerve: new method and its clinical application..  24:689-694. 2001

Distal sensory nerve conduction of the superficial peroneal nerve: New method and its clinical application.  24:689-694. 2001

Lateral plantar neuropathy.  22:1234-1238. 1999

New near-nerve needle nerve conduction technique: Differentiating epicondylar from cubital tunnel ulnar neuropathy.  22:718-723. 1999

Reply.  21:1812-1813. 1998

Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome [3].  21:1107-1108. 1998

Anti-Hu-associated paraneoplastic sensory neuronopathy responding to early aggressive immunotherapy: Report of two cases and review of literature.  20:1576-1582. 1997

Low-dose guanidine and pyridostigmine: Relatively safe and effective long-term symptomatic therapy in lambert-eaton myasthenic syndrome.  20:1146-1152. 1997

Stiff-persons' syndrome associated with thymoma and subsequent myasthenia gravis.  20:493-498. 1997

Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome.  19:903-906. 1996

Combined motor and sensory median-ulnar anastomosis: Report of an electrophysiologically proven case.  19:231-233. 1996

Isaacs' syndrome associated with chronic inflammatory demyelinating polyneuropathy.  19:210-215. 1996

A macro‐EMG study in charonic demyelinating neuropathy.  18:348-350. 1995

Double anastomosis of median–ulnar and ulnar–median nerves: Report of an electrophysiologically proven case.  18:1332-1334. 1995

Electrophysiological studies in Joplin's neuroma.  18:671-672. 1995

Peroneal nerve repetitive nerve stimulation test: Its value in diagnosis of myasthenia gravis and Lambert–Eaton myasthenic syndrome.  18:867-873. 1995

Clinical and electromyographic correlations of lumbosacral radiculopathy [4].  17:250-251. 1994

Early appearance of aging phenomenon in the interdigital nerves of the foot.  17:58-63. 1994

Letters to the editor.  17:245-253. 1994

Myokymia–cramp syndrome: Evidence of hyperexcitable peripheral nerve.  17:1065-1067. 1994

Tendon‐reflex testing in chronic demyelinating polyneuropathy.  17:145-150. 1994

What is the best diagnostic index of conduction block and temporal dispersion?.  17:489-493. 1994

Electromyography in benign congenital myopathies [6].  16:328. 1993

Letters to the editor.  16:321-328. 1993

Primary respiratory failure as the presenting symptom in Lambert–Eaton myasthenic syndrome.  16:712-715. 1993

A case of chronic sensory demyelinating neuropathy responding to immunotherapies..  15:255-256. 1992

Conduction block in hereditary motor sensory neuropathy, type I: Case report [9].  15:521-523. 1992

Diagnostic sensitivity of the laboratory tests in myasthenia gravis.  15:720-724. 1992

Letters to the editor.  15:255-258. 1992

Letters to the editor.  15:513-523. 1992

Electrophysiological improvement following decompression surgery in tarsal tunnel syndrome.  14:407-410. 1991

Paraneoplastic vasculitic neuropathy: A treatable neuropathy.  14:152-156. 1991

Hereditary motor and sensory neuropathy.  14:85-86. 1990

Edrophonium responsiveness not necessarily diagnostic of myasthenia gravis.  13:187-191. 1990

Edrophonium responsiveness not necessarily diagnostic of myasthenia gravis: A reply.  13:1186. 1990

Electrophysiological spectrum of inclusion body myositis.  13:949-951. 1990

Letters to the editor.  13:1183-1186. 1990

The single-fiber EMG in the Lambert-Eaton myasthenic syndrome..  12:159-160. 1989

Asymptomatic hyper‐CK‐emia: An electrophysiologic and histopathologic study.  12:206-209. 1989

Diverse electrophysiological spectrum of the Lambert–Eaton myasthenic syndrome.  12:464-469. 1989

Letters to the editor.  12:156-163. 1989

SFEMG improvement with remission in the cancer‐associated Lambert–Eaton myasthenic syndrome.  12:844-848. 1989

The single‐fiber EMG in chronic demyelinating neuropathy.  12:371-377. 1989

Letters to the editor.  10:670-672. 1987

Procainamide-induced myasthenia-like syndrome..  9:670-672. 1986

Letters to the Editor.  9:669-672. 1986

Electrophysiological diagnosis of interdigital neuropathy of the foot.  7:218-225. 1984

A benign form of reducing body myopathy.  6:278-282. 1983

Multiple sclerosis and hypertrophic demyelinating peripheral neuropathy.  6:312-316. 1983

Preparation of cell‐free extracellular matrix from human peripheral nerve.  5:335-344. 1982